← brief for 2026-08-12 · Slowing decline

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Trial No results yet Not peer reviewed

Key takeaways

This large five-year trial tests orforglipron, a once-daily GLP-1 pill, against a placebo. It asks whether the pill prevents heart attacks and strokes in people with heart disease, chronic kidney disease, or both. The study is just opening, so there are no results yet.

Who did this work

Run by Eli Lilly and Company. Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (Eli Lilly and Company)
Sites: Instituto de Investigaciones Clínicas Bahia Blanca · CONEXA Investigacion Clinica S.A. · Buenos Aires Macula S.A · CIPREC · Instituto Médico Especializado (IME) · Cicemo Srl

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-06
https://clinicaltrials.gov/study/NCT07241390